All Oncology News

Yufei Liu, MD, PhD, discusses current radiation strategies, including SBRT and IMRT, along with the benefits of radiation therapy in colorectal cancer.

Thejal Srikumar, MD, MPH, discusses the Yale School of Medicine's unique approach to offering fellows a space to address professional burnout.

A randomized trial found no significant differences in recurrence or survival with smaller radiation margins vs standard RTOG protocols in patients with HGG.

A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.

Benjamin Herzberg, MD, details research in KRAS G12C-mutated NSCLC with divarasib and how he currently selects between available therapies in this space.

Moffitt Cancer Center researchers found a way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure.

A Type II variation application has been submitted to the EMA for the expanded approval of sugemalimab for unresectable stage III NSCLC.

The combination of toripalimab and bevacizumab has been approved in China for the treatment of patients with unresectable or metastatic HCC.

Raajit Rampal, MD, PhD, discusses current JAK inhibitor treatment options for myelofibrosis and additional therapies being evaluated in clinical trials.

Jill Gilbert, MD, discusses professional strategy techniques that she has found useful through incredibly challenging times.

Enfortumab vedotin demonstrated a manageable safety profile and no unexpected toxicities in patients aged 80 years and older with urothelial carcinoma.

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

The risk of developing ICANS with CAR T-cell therapy was higher in patients with NHL who experienced a recent fall and could not balance on their left leg.

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

Adjuvant HRQOL outcomes improved in patients with bladder cancer living in rural areas and were worse with ADT plus radiotherapy after prostatectomy.

Shruti Patel, MD, highlights women making strides to improve cancer care and the need for equitable gender representation among oncology researchers.

Tanya Gupta, MD, details FDA-approved CDK4/6 inhibitors and considerations for selecting treatment in HR-positive, HER2-negative metastatic breast cancer.

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new genetic therapy to treat glioblastoma.

R. Lor Randall, MD, FACS, discusses the development of a bone marrow matrix to study osteosarcoma and the model’s mechanisms of metastasis control.

China’s NMPA has granted conditional approval to the EZH2 inhibitor tazemetostat for patients with relapsed/refractory EZH2-mutated follicular lymphoma.

PLN-101095 plus pembrolizumab was safe and active in immune checkpoint inhibitor–refractory advanced solid tumors.

For Anal Cancer Awareness Day, Sheela Rao, MBBS, MD, FRCP, discusses present and upcoming treatment strategies, unmet needs, and the future of the field.

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends in gynecologic cancer care discussed during the 2025 SGO Annual Meeting.

Joshua Feinberg, MD, discusses the role of the Scout AI platform in aiding trial matching and treatment selection in oncology.

Real-world data showed that atezolizumab provided a benefit and was safe in patients with platinum-ineligible mUC and high comorbidities/functional status.

The FDA has approved TLX007-CDx as an imaging agent in select patients with prostate cancer.

Kelly E. McCann, MD, discusses mentorship in oncology and the importance of guiding patients with breast cancer through their treatment journey.

Andreas M. Kaiser, MD, discusses strategies to reduce postoperative complications and determine surgical eligibility in patients with CRC.

Reshma Jagsi, MD, DPhil, highlights her journey to becoming a radiation oncologist and the nuances of intersectionality as a woman in oncology.

Roswell Park Comprehensive Cancer Center has been recognized as a Center of Excellence for both adult and pediatric cancer treatment by Optum.